| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke Rehabilitation | 9 | 2022 | 335 | 1.200 |
Why?
|
| Research Design | 4 | 2021 | 729 | 0.950 |
Why?
|
| Stroke | 12 | 2022 | 2163 | 0.800 |
Why?
|
| Upper Extremity | 8 | 2022 | 112 | 0.660 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 848 | 0.600 |
Why?
|
| Infant, Premature | 4 | 2021 | 284 | 0.500 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2017 | 296 | 0.490 |
Why?
|
| Progesterone | 3 | 2022 | 115 | 0.480 |
Why?
|
| Treatment Outcome | 16 | 2022 | 7029 | 0.450 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2013 | 20 | 0.450 |
Why?
|
| Proteomics | 1 | 2014 | 246 | 0.420 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 306 | 0.410 |
Why?
|
| Peptides | 1 | 2014 | 455 | 0.390 |
Why?
|
| Craving | 5 | 2022 | 200 | 0.380 |
Why?
|
| Computer Simulation | 4 | 2022 | 706 | 0.350 |
Why?
|
| Humans | 53 | 2022 | 68618 | 0.350 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2021 | 756 | 0.340 |
Why?
|
| Private Practice | 1 | 2009 | 19 | 0.330 |
Why?
|
| Smokers | 2 | 2022 | 200 | 0.330 |
Why?
|
| Stress, Psychological | 4 | 2022 | 824 | 0.330 |
Why?
|
| Cocaine-Related Disorders | 4 | 2018 | 504 | 0.320 |
Why?
|
| Hospitals, University | 1 | 2009 | 169 | 0.320 |
Why?
|
| Models, Statistical | 3 | 2019 | 448 | 0.320 |
Why?
|
| Hydrocortisone | 3 | 2022 | 291 | 0.310 |
Why?
|
| Endpoint Determination | 2 | 2019 | 82 | 0.310 |
Why?
|
| Status Epilepticus | 1 | 2009 | 74 | 0.310 |
Why?
|
| Hand | 4 | 2022 | 90 | 0.290 |
Why?
|
| Saliva | 4 | 2022 | 142 | 0.290 |
Why?
|
| Residence Characteristics | 1 | 2009 | 252 | 0.280 |
Why?
|
| Tobacco Products | 2 | 2020 | 234 | 0.280 |
Why?
|
| Estradiol | 2 | 2020 | 176 | 0.280 |
Why?
|
| Limb Salvage | 1 | 2006 | 39 | 0.280 |
Why?
|
| Olfaction Disorders | 2 | 2022 | 100 | 0.270 |
Why?
|
| Femoral Artery | 1 | 2006 | 139 | 0.270 |
Why?
|
| Angioplasty, Balloon | 1 | 2006 | 110 | 0.270 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 134 | 0.260 |
Why?
|
| Young Adult | 13 | 2022 | 5717 | 0.260 |
Why?
|
| Ischemia | 1 | 2006 | 229 | 0.250 |
Why?
|
| Recovery of Function | 7 | 2022 | 506 | 0.250 |
Why?
|
| Cues | 4 | 2020 | 654 | 0.250 |
Why?
|
| Adult | 22 | 2022 | 21403 | 0.250 |
Why?
|
| Lower Extremity | 1 | 2006 | 153 | 0.250 |
Why?
|
| Sex Characteristics | 2 | 2019 | 295 | 0.250 |
Why?
|
| Middle Aged | 21 | 2022 | 21147 | 0.250 |
Why?
|
| Female | 29 | 2022 | 38074 | 0.240 |
Why?
|
| Regression Analysis | 3 | 2017 | 737 | 0.240 |
Why?
|
| Prospective Studies | 9 | 2020 | 3705 | 0.230 |
Why?
|
| Probability | 2 | 2021 | 245 | 0.230 |
Why?
|
| Random Allocation | 2 | 2021 | 442 | 0.220 |
Why?
|
| Electroencephalography | 3 | 2022 | 418 | 0.220 |
Why?
|
| Male | 26 | 2022 | 37321 | 0.220 |
Why?
|
| Causality | 1 | 2022 | 82 | 0.200 |
Why?
|
| Biostatistics | 2 | 2018 | 43 | 0.190 |
Why?
|
| Cocaine | 2 | 2022 | 555 | 0.190 |
Why?
|
| Bias | 1 | 2021 | 148 | 0.190 |
Why?
|
| Adolescent | 10 | 2022 | 8912 | 0.190 |
Why?
|
| Smoking Cessation | 3 | 2020 | 1034 | 0.180 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2022 | 86 | 0.180 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2020 | 37 | 0.180 |
Why?
|
| Infant, Premature, Diseases | 1 | 2021 | 85 | 0.180 |
Why?
|
| Quality of Life | 6 | 2022 | 1515 | 0.180 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 319 | 0.180 |
Why?
|
| Nicotine | 2 | 2015 | 350 | 0.180 |
Why?
|
| Rhinitis | 2 | 2016 | 383 | 0.180 |
Why?
|
| Infant, Newborn | 6 | 2021 | 2455 | 0.180 |
Why?
|
| Neuroprotective Agents | 2 | 2020 | 317 | 0.180 |
Why?
|
| Developmental Disabilities | 2 | 2018 | 119 | 0.180 |
Why?
|
| Tobacco Smoking | 1 | 2020 | 41 | 0.180 |
Why?
|
| Acute Coronary Syndrome | 1 | 2021 | 195 | 0.180 |
Why?
|
| Menstrual Cycle | 2 | 2022 | 64 | 0.180 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 116 | 0.170 |
Why?
|
| Hospital Charges | 1 | 2020 | 60 | 0.170 |
Why?
|
| Heart Diseases | 1 | 2022 | 276 | 0.170 |
Why?
|
| Peer Influence | 1 | 2019 | 7 | 0.170 |
Why?
|
| Sinusitis | 2 | 2016 | 432 | 0.170 |
Why?
|
| Telerehabilitation | 1 | 2019 | 6 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 16 | 0.170 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2020 | 59 | 0.170 |
Why?
|
| Cortical Synchronization | 1 | 2019 | 6 | 0.160 |
Why?
|
| Aged | 12 | 2021 | 14862 | 0.160 |
Why?
|
| Motor Disorders | 1 | 2018 | 4 | 0.160 |
Why?
|
| S-Nitrosoglutathione | 1 | 2020 | 87 | 0.160 |
Why?
|
| Sensorimotor Cortex | 1 | 2019 | 18 | 0.160 |
Why?
|
| Touch Perception | 1 | 2019 | 18 | 0.160 |
Why?
|
| Brain Waves | 1 | 2019 | 30 | 0.160 |
Why?
|
| Mentoring | 1 | 2019 | 53 | 0.160 |
Why?
|
| Parkinson Disease | 1 | 2022 | 272 | 0.160 |
Why?
|
| Cerebral Palsy | 1 | 2018 | 24 | 0.160 |
Why?
|
| Catheter Ablation | 1 | 2021 | 229 | 0.160 |
Why?
|
| Bibliometrics | 1 | 2018 | 25 | 0.160 |
Why?
|
| Publications | 1 | 2018 | 17 | 0.160 |
Why?
|
| Social Environment | 1 | 2020 | 182 | 0.160 |
Why?
|
| Foot | 1 | 2018 | 66 | 0.160 |
Why?
|
| Muscle Strength | 1 | 2018 | 62 | 0.160 |
Why?
|
| KCNQ Potassium Channels | 1 | 2018 | 8 | 0.160 |
Why?
|
| Self-Management | 1 | 2019 | 82 | 0.160 |
Why?
|
| Task Performance and Analysis | 1 | 2019 | 150 | 0.150 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 104 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 84 | 0.150 |
Why?
|
| Oxytocin | 1 | 2019 | 124 | 0.150 |
Why?
|
| Movement | 2 | 2019 | 179 | 0.150 |
Why?
|
| Postural Balance | 1 | 2018 | 93 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 207 | 0.150 |
Why?
|
| Behavior, Addictive | 2 | 2020 | 317 | 0.150 |
Why?
|
| Accidental Falls | 1 | 2018 | 84 | 0.150 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2018 | 69 | 0.150 |
Why?
|
| Parathyroid Hormone | 1 | 2018 | 117 | 0.150 |
Why?
|
| Medicaid | 1 | 2020 | 302 | 0.150 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 424 | 0.150 |
Why?
|
| Electric Stimulation Therapy | 1 | 2019 | 147 | 0.150 |
Why?
|
| Child Development | 2 | 2015 | 102 | 0.140 |
Why?
|
| Premature Birth | 1 | 2018 | 150 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 498 | 0.140 |
Why?
|
| Respiratory System Agents | 1 | 2016 | 4 | 0.130 |
Why?
|
| Muscle Relaxation | 1 | 2015 | 31 | 0.130 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2017 | 117 | 0.130 |
Why?
|
| Health Behavior | 1 | 2019 | 458 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 396 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2018 | 342 | 0.130 |
Why?
|
| Double-Blind Method | 6 | 2019 | 1738 | 0.130 |
Why?
|
| Hospitalization | 2 | 2020 | 978 | 0.130 |
Why?
|
| Evoked Potentials, Motor | 1 | 2015 | 63 | 0.130 |
Why?
|
| Hand Strength | 1 | 2015 | 47 | 0.130 |
Why?
|
| Infant | 4 | 2021 | 2891 | 0.130 |
Why?
|
| Drug-Seeking Behavior | 1 | 2018 | 213 | 0.130 |
Why?
|
| Poisson Distribution | 1 | 2015 | 85 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 581 | 0.120 |
Why?
|
| United States | 5 | 2021 | 7367 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 109 | 0.120 |
Why?
|
| Normal Distribution | 1 | 2014 | 46 | 0.120 |
Why?
|
| Guanfacine | 1 | 2014 | 6 | 0.120 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 11 | 0.120 |
Why?
|
| Quinoxalines | 1 | 2015 | 78 | 0.120 |
Why?
|
| Benzazepines | 1 | 2015 | 104 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 232 | 0.120 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2019 | 413 | 0.120 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2014 | 15 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 111 | 0.120 |
Why?
|
| Motor Skills Disorders | 1 | 2014 | 7 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 191 | 0.120 |
Why?
|
| Yohimbine | 1 | 2014 | 41 | 0.120 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 59 | 0.110 |
Why?
|
| Vitamin D | 1 | 2018 | 516 | 0.110 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2015 | 111 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 767 | 0.110 |
Why?
|
| Smoking | 2 | 2020 | 1452 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2021 | 7277 | 0.110 |
Why?
|
| Cluster Analysis | 3 | 2022 | 219 | 0.110 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2013 | 3 | 0.110 |
Why?
|
| Motor Skills | 1 | 2014 | 88 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2013 | 75 | 0.110 |
Why?
|
| Pneumonectomy | 1 | 2013 | 79 | 0.110 |
Why?
|
| Scleroderma, Systemic | 1 | 2017 | 446 | 0.110 |
Why?
|
| Pulmonary Emphysema | 1 | 2013 | 71 | 0.110 |
Why?
|
| Taste Disorders | 1 | 2012 | 3 | 0.100 |
Why?
|
| Zinc Sulfate | 1 | 2012 | 4 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2014 | 191 | 0.100 |
Why?
|
| Leukemia | 1 | 2013 | 117 | 0.100 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 640 | 0.100 |
Why?
|
| Bronchoscopy | 1 | 2013 | 147 | 0.100 |
Why?
|
| Ammonia | 1 | 2011 | 28 | 0.100 |
Why?
|
| Recurrence | 3 | 2021 | 948 | 0.100 |
Why?
|
| Linear Models | 3 | 2018 | 521 | 0.100 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2022 | 150 | 0.100 |
Why?
|
| Pituitary-Adrenal System | 2 | 2022 | 138 | 0.100 |
Why?
|
| Time Factors | 4 | 2019 | 4655 | 0.100 |
Why?
|
| Arteries | 1 | 2011 | 108 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2013 | 880 | 0.090 |
Why?
|
| Anxiety | 1 | 2014 | 422 | 0.090 |
Why?
|
| Aging | 1 | 2015 | 911 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 468 | 0.090 |
Why?
|
| Databases, Bibliographic | 1 | 2009 | 14 | 0.080 |
Why?
|
| Brain | 1 | 2020 | 2176 | 0.080 |
Why?
|
| Wrist | 2 | 2019 | 24 | 0.080 |
Why?
|
| Virginia | 1 | 2009 | 45 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 3259 | 0.080 |
Why?
|
| Vibration | 2 | 2019 | 32 | 0.080 |
Why?
|
| Physical Stimulation | 2 | 2019 | 67 | 0.080 |
Why?
|
| Age Distribution | 1 | 2009 | 320 | 0.080 |
Why?
|
| Prognosis | 3 | 2022 | 2093 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2009 | 182 | 0.080 |
Why?
|
| Forced Expiratory Volume | 2 | 2020 | 87 | 0.070 |
Why?
|
| Markov Chains | 2 | 2018 | 133 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2016 | 1330 | 0.070 |
Why?
|
| Gangrene | 1 | 2006 | 11 | 0.070 |
Why?
|
| Electromyography | 2 | 2019 | 184 | 0.070 |
Why?
|
| Intermittent Claudication | 1 | 2006 | 31 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2006 | 59 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 931 | 0.070 |
Why?
|
| Vascular Patency | 1 | 2006 | 122 | 0.070 |
Why?
|
| Radiography, Interventional | 1 | 2006 | 49 | 0.070 |
Why?
|
| Phenotype | 2 | 2022 | 947 | 0.070 |
Why?
|
| Angiography | 1 | 2006 | 194 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1851 | 0.070 |
Why?
|
| Sex Factors | 2 | 2020 | 1266 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2006 | 536 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2019 | 307 | 0.060 |
Why?
|
| Reoperation | 1 | 2006 | 467 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2021 | 2007 | 0.060 |
Why?
|
| Incidence | 1 | 2009 | 1603 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 1070 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2018 | 517 | 0.060 |
Why?
|
| Pain | 1 | 2006 | 472 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4848 | 0.050 |
Why?
|
| Luteal Phase | 1 | 2022 | 25 | 0.050 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2022 | 13 | 0.050 |
Why?
|
| Stents | 1 | 2006 | 657 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2009 | 3187 | 0.050 |
Why?
|
| Clonidine | 1 | 2021 | 66 | 0.050 |
Why?
|
| Globus Pallidus | 1 | 2022 | 64 | 0.050 |
Why?
|
| Symptom Flare Up | 1 | 2021 | 20 | 0.050 |
Why?
|
| Accelerometry | 1 | 2021 | 61 | 0.050 |
Why?
|
| Smell | 1 | 2022 | 131 | 0.050 |
Why?
|
| Patient Navigation | 1 | 2021 | 30 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2020 | 12 | 0.050 |
Why?
|
| Heart Septum | 1 | 2021 | 84 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 1420 | 0.050 |
Why?
|
| Gait | 1 | 2022 | 120 | 0.050 |
Why?
|
| Bundle-Branch Block | 1 | 2021 | 50 | 0.050 |
Why?
|
| Gastrostomy | 1 | 2021 | 110 | 0.050 |
Why?
|
| Alcoholism | 1 | 2009 | 1109 | 0.050 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2020 | 61 | 0.050 |
Why?
|
| Gestational Age | 1 | 2021 | 389 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 26 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 88 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 652 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 208 | 0.040 |
Why?
|
| Algorithms | 2 | 2016 | 1196 | 0.040 |
Why?
|
| Dopamine | 1 | 2022 | 474 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 145 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 59 | 0.040 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2018 | 12 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 319 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2022 | 274 | 0.040 |
Why?
|
| Benchmarking | 1 | 2019 | 91 | 0.040 |
Why?
|
| Research | 1 | 2019 | 214 | 0.040 |
Why?
|
| Phenylenediamines | 1 | 2018 | 16 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2324 | 0.040 |
Why?
|
| Membrane Transport Modulators | 1 | 2018 | 23 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 83 | 0.040 |
Why?
|
| Carbamates | 1 | 2018 | 41 | 0.040 |
Why?
|
| Child | 1 | 2009 | 6405 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2018 | 203 | 0.040 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2017 | 25 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 733 | 0.040 |
Why?
|
| Bone Density | 1 | 2018 | 159 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 189 | 0.040 |
Why?
|
| Action Potentials | 1 | 2018 | 223 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 329 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 103 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2016 | 36 | 0.030 |
Why?
|
| H-Reflex | 1 | 2015 | 15 | 0.030 |
Why?
|
| Psychometrics | 1 | 2018 | 514 | 0.030 |
Why?
|
| Salmonella | 1 | 2015 | 20 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 292 | 0.030 |
Why?
|
| Transdermal Patch | 1 | 2015 | 21 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2015 | 27 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1342 | 0.030 |
Why?
|
| Varenicline | 1 | 2015 | 98 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 419 | 0.030 |
Why?
|
| Head | 1 | 2015 | 59 | 0.030 |
Why?
|
| Ethanol | 1 | 2021 | 893 | 0.030 |
Why?
|
| Endothelin-Converting Enzymes | 1 | 2014 | 15 | 0.030 |
Why?
|
| Dehydroepiandrosterone | 1 | 2014 | 29 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 148 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 622 | 0.030 |
Why?
|
| Endosomes | 1 | 2014 | 45 | 0.030 |
Why?
|
| Echocardiography | 1 | 2017 | 515 | 0.030 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2014 | 47 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 2014 | 67 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 649 | 0.030 |
Why?
|
| Motor Cortex | 1 | 2015 | 158 | 0.030 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 27 | 0.030 |
Why?
|
| Proteolysis | 1 | 2014 | 97 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2015 | 368 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 260 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2013 | 14 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2015 | 213 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2013 | 19 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 41 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 2083 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2077 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 97 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 84 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Flavonoids | 1 | 2013 | 109 | 0.030 |
Why?
|
| Piperidines | 1 | 2013 | 123 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 174 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 20881 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 658 | 0.020 |
Why?
|
| Tobacco | 1 | 2011 | 161 | 0.020 |
Why?
|
| South Carolina | 1 | 2017 | 2752 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 5300 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 981 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2673 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2358 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2007 | 80 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2800 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 195 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 1173 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 334 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2007 | 289 | 0.020 |
Why?
|
| Heart Rate | 1 | 2007 | 568 | 0.020 |
Why?
|
| Neoplasms | 1 | 2012 | 1667 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 1451 | 0.010 |
Why?
|